Effect of hyaluronic acid on vaginal atrophy in postmenopausal women

The Comparison of the effects of hyaluronic acid and conjugated estrogen vaginal cream (Prmarin) on vaginal atrophy in menopausal women referred to selected clinics affiliated to Shiraz university of medical sciences, 1391

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013022712644N1

Enrollment

Registered

2013-09-15

Start date

2013-08-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal atrophy. Senile (atrophic) vaginitis

Interventions

Intervention 1: Conjugated estrogen vaginal cream drug (Prmaryn) to a group of patients / eight weeks / two weeks remaining in the first row and the same dose twice a week for six weeks. Intervention

Treatment - Drugs

Conjugated estrogen vaginal cream drug (Prmaryn) to a group of patients / eight weeks / two weeks remaining in the first row and the same dose twice a week for six weeks.

Hyaluronic acid vaginal cream medication to a group of patient / eight weeks

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Major inclusion criteria: Married women past menopause who have symptoms?Non-Smoking? The use of drugs such as Heparin anticoagulants? Vaginal dryness and moderate to severe pain in the area during intercourse. (measured by visual criteria)? Do not use vaginal medications, hormonal and non-hormonal treatment for 30 days before? No history of known or suspected hormone-dependent diseases such as (breast cancer, cases of unexplained vaginal bleeding, acute Phlebitis or Thromboembolic disorders associated with estrogen and ...) Major exclusion criteria: Need to cure vaginal infection in primary screening for Pap smear? Sensitivity (rash, erythema, inflammation, ...) to the drug or its ingredients? Lack of desire to continue working

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Maturity of vagina. Timepoint: Before and after eight weeks (end of intervention). Method of measurement: Calculate the percentage of cells in pap smear.;Vaginal PH. Timepoint: Before and after eight weeks (end of intervention). Method of measurement: By PH meter strips.	—

Secondary

Measure	Time frame
Vaginal dryness. Timepoint: Before and after the intervention. Method of measurement: VAS.;Vaginal itching. Timepoint: Before and after the intervention. Method of measurement: VAS.;Urine incontinence. Timepoint: Before and after the intervention. Method of measurement: VAS.;Dyspareunia. Timepoint: Before and after the intervention. Method of measurement: VAS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTayebe Davari Dehpiri

College of Nursing and Midwifery, Shiraz

davarit@sums.ac.ir+98 71 1647 4254

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026